9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Estimated reading time: < 1 min

Condition: Advanced Solid Tumors Cancer

Estimated Enrollment: 170

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Terminal half-life (t1/2) of ABBV-368,  Area under the serum concentration-time curve (AUC) of ABBV-368,  Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181, Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181

Interventions: ABBV-368, ABBV-181

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: June 15, 2020

Completion Date: September 17, 2020

Last  Posted Date: June 10, 2019

Location: Ucsd /Id# 201334, La Jolla, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03071757

Was this article helpful?
Dislike 0